At a glance
| Structure | Nine-amino-acid cyclic peptide |
|---|---|
| Main medical action | Stimulates uterine contractions |
| Established setting | Labor and postpartum care |
| Key monitoring | Uterine activity and fetal/maternal status |
| Serious risk | Uterine hyperstimulation and water intoxication |
| Behavioral uses | Separate investigational evidence |
Overview
Natural oxytocin participates in uterine contraction and milk ejection, while pharmaceutical oxytocin is used in monitored maternity care for specific obstetric purposes. The US injectable label includes medically indicated labor induction, selected augmentation of labor, adjunctive management of incomplete or inevitable abortion, and production of uterine contractions to control postpartum bleeding. Appropriate use depends on maternal and fetal assessment and whether vaginal delivery is suitable. Intranasal oxytocin investigated for behavioral or psychiatric effects is a separate research context; the established obstetric record does not automatically validate those applications or an unapproved compounded formulation.
How it works
Oxytocin activates oxytocin receptors on uterine smooth-muscle cells, engaging intracellular signaling that increases calcium and promotes contraction. Uterine sensitivity varies with pregnancy and clinical context. After delivery, contraction helps compress uterine blood vessels and limit bleeding. At higher or prolonged exposure, oxytocin’s antidiuretic activity can also influence water balance, contributing to the risk of water intoxication and low sodium.
Where is oxytocin established?
The injectable label describes medically indicated induction or reinforcement of suitable labor and control of postpartum uterine bleeding. It also includes adjunctive management of incomplete or inevitable abortion. Suitability depends on the obstetric situation; circumstances requiring surgical delivery or making vaginal delivery unsafe are important contraindications.
Supporting sources [1]
Does the obstetric evidence prove behavioral benefit?
No. A 24-week placebo-controlled trial in 290 children and adolescents with autism found no significant advantage for intranasal oxytocin on the primary social-withdrawal measure. This result does not erase oxytocin’s obstetric utility; it shows that effects depend on route, population and clinical outcome.
Supporting sources [2]
Why is monitoring essential?
Excessive uterine activity can compromise fetal oxygenation and can cause serious maternal injury, including uterine rupture. Prolonged administration can cause water intoxication, hyponatremia and seizures. Appropriate assessment of contractions, fetal status, fluid balance and the overall maternal condition is fundamental to safe clinical use.
Supporting sources [1]
Is a “bonding hormone” label a treatment indication?
No. A hormone’s physiological role does not establish that administering it improves relationships, sexual function, mood or social behavior. Those questions require their own controlled studies and product-specific evaluation. Approved injectable oxytocin for obstetric care should not be presented as approval of intranasal wellness products.
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Cyclic nonapeptide hormone and uterotonic medicine.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Oxytocin injection — current US prescribing information ↗Regulatory source · Checked 2026-10-27
- Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder ↗Original research · Checked 2026-10-27